Abstract
No studies have examined the impact of human papillomavirus (HPV)-16 and HPV-18 on survival, inflammation biomarkers, and immune function in early-stage cervical cancer patients undergoing surgery. Patients diagnosed with early-stage cervical cancer were screened for high-risk HPV prior to surgery. The influence of HPV infection on survival, inflammatory markers, and immune function was investigated. Findings revealed that patients in the HPV-18 positive subgroup exhibited poorer disease-free survival (DFS) and elevated levels of interleukin-6 and C-reactive protein, along with decreased CD4+ T cells compared to patients who tested negative for HPV-18. Notably, early-stage cervical cancer patients with HPV-18 infection experienced worse DFS, heightened inflammatory markers, and compromised immune function.